Latest Breaking News On - Sarepta therapeutics company profile - Page 5 : comparemela.com

Zacks Research Brokers Raise Earnings Estimates for Sarepta Therapeutics, Inc (NASDAQ:SRPT)

Zacks Research Brokers Raise Earnings Estimates for Sarepta Therapeutics, Inc (NASDAQ:SRPT)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

New zealand generalNew zealandRichard barryDouglass ingramHandelsinvest investeringsforvaltningVanguard group incZacks researchRoyal bankSarepta therapeutics incSarepta therapeutics company profileWellington management groupSarepta therapeuticsFree reportSarepta therapeuticGet free reportTherapeutics stock down

Q3 2024 Earnings Estimate for Sarepta Therapeutics, Inc Issued By Zacks Research (NASDAQ:SRPT)

Q3 2024 Earnings Estimate for Sarepta Therapeutics, Inc Issued By Zacks Research (NASDAQ:SRPT)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

New zealand generalNew zealandDouglass ingramRichard barrySarepta therapeutics company profileSarepta therapeutics incSecurities exchange commissionZacks researchWellington management groupBlackrock incRoyal bankMorgan stanleyYork mellon corpVanguard group incSarepta therapeuticsFree report

Artia Global Partners LP Increases Holdings in Sarepta Therapeutics, Inc (NASDAQ:SRPT)

Artia Global Partners LP raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 28.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,162 shares of the biotechnology company’s stock after buying an additional 17,162 shares during the […]

Douglass ingramRichard barryJennison associatesSecurities exchange commissionExchange commissionSarepta therapeutics company profileYork mellon corpTekla capital managementCantor fitzgeraldSarepta therapeutics incJpmorgan chase coFirst horizon advisors incMorgan stanleyArtia global partnersSarepta therapeuticsFree report

Sarepta Therapeutics, Inc (NASDAQ:SRPT) Given Consensus Recommendation of Moderate Buy by Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have received an average recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1 year […]

Richard barryDouglass ingramJpmorgan chase coRoyal bankMontaga associates incPartners investment advisoryFirst horizon advisors incSarepta therapeutics company profileSarepta therapeutics incSecurities exchange commissionQube research technologies ltdSarepta therapeuticsGet free reportDirector richard barryExchange commissionWealth management

Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Analysts at Wedbush

Wedbush began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $224.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2023 earnings at $0.04 EPS, FY2023 earnings […]

Douglass ingramRichard barryDimensional fund advisorsNeedham companySarepta therapeutics company profileGreat west life assurance coSarepta therapeutics incSecurities exchange commissionHealthcare of ontario pension plan trust fundFinancial services group incMetlife investment managementCantor fitzgeraldMorgan stanleySarepta therapeuticsFree reportMarketbeat ratings